Visterra
Bringing better biologics to life.
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2007
- Business Model
- B2B
- Website
- visterra.com
- Total Funding
- $116.1M
- Last Round
- $23.6M Series COct 2017
About
Visterra is a biologics research and early-stage clinical development company focused on developing novel therapeutics for patients with immune-mediated and other hard-to-treat diseases. The company applies cutting-edge computational, AI, and experimental research methods alongside agile preclinical development to engineer next-generation antibody-based therapies. Visterra's lead program, sibeprenlimab (VIS171), targets IgA nephropathy (IgAN) and has received FDA acceptance and Priority Review designation. The company leverages a unique platform combining structural biology, computational design, and proprietary antibody engineering to develop differentiated biologics. Originally spun out of MIT, Visterra was founded in 2007 and is based in Cambridge, Massachusetts. The company was acquired by Otsuka Holdings, which continues to advance its clinical pipeline.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account